US regulator approves pill form of Wegovy weight-loss drug
The US FDA has approved a pill form of Wegovy, a weight-loss drug made by Novo Nordisk, marking the first such approval for a weight-loss pill in the US. The once-daily pill is designed to provide the same weight loss as the injectable version, with trials showing an average weight loss of 16.6%.

Briefing Summary
AI-generatedThe US FDA has approved a pill form of Wegovy, a weight-loss drug made by Novo Nordisk, marking the first such approval for a weight-loss pill in the US. The once-daily pill is designed to provide the same weight loss as the injectable version, with trials showing an average weight loss of 16.6%. Novo Nordisk plans to launch the pill in the US in early January 2026, offering a more convenient option for patients. The approval could boost Novo Nordisk's sales amidst competition in the weight-loss market, and its shares rose following the announcement. While other drugs like Ozempic have weight-loss effects, Wegovy was specifically approved for weight loss.
Article analysis
Model · rule-basedKey claims
5 extractedNovo Nordisk's shares rose by almost 10% in after-hours trade in New York after the announcement.
A third of around 1,300 participants experienced 20% or greater weight loss in the same trial.
The Wegovy pill showed an average weight loss of 16.6% during Novo Nordisk's trials.
The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy.
Patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection.